Outcome Capital, an investment banking firm that serves middle market growth companies in life sciences and technology markets, has expanded its operations into Europe with the opening of a UK office in London.
The company has appointed Shawn Manning as managing director of the new office.
Outcome Capital has been working closely with the UK Department for International Trade to set up the London Office.
“In addition to providing background research on the life sciences ecosystem in the UK, we continue to support Outcome by helping identify UK companies that may meet their M&A and investment criteria,” says John Maclennan, vice consul, US sector lead for life sciences at the UK Department for International Trade.
Oded Ben-Joseph, managing director at Outcome Capital, says: “By increasing access to both European capital and M&A opportunities, the addition of our London office significantly broadens the services and value we bring to our clients. We aim to provide a platform for US and European companies to acquire high-value product assets and broaden their market access. We continue to be passionate about bringing paradigm-shifting technologies to patients and are excited by the opportunity to facilitate transatlantic collaborations between Boston’s biotech hub and the life sciences-rich Oxford/Cambridge/London ‘Golden Triangle’."
Manning has more than 25 years of international experience in the life sciences, including more than three years as founder and managing director at Akesios Associates and more than 12 years as a rated equity analyst covering large pharma, speciality/emerging pharmaceutical, and biotechnology stocks at Dresdner Kleinwort Benson, SG-Cowen/ Société Generale, Bridgewell/ Landsbanki and Singer Capital Markets. Since 2005, his research has supported the raise of more than GBP500 million in new funding for life science companies.
Previously, Manning spent five years as a consultant to the pharmaceutical industry and managed Datamonitor’s healthcare practice. In this capacity, he worked alongside major European, US and Japanese pharmaceutical companies, leading projects focused primarily on strategic product positioning, including portfolio, opportunity and pricing analysis.
“I was drawn to Outcome Capital by its strong track record of value-enhancing life science transactions, its client-centric business model, and the high standards, creativity and flexibility they bring to the table,” says Manning. “The broad range of experience across the Outcome team truly differentiates it from many of its investment banking peers. I am excited for the opportunity to expand the firm’s impact in Europe and with US companies interested in working with European strategic partners or investors.”
Arnold Freedman, managing director at Outcome Capital, adds: “We are delighted to bring Shawn on board to launch our operations in Europe. He brings to Outcome Capital significant experience with the UK and European Capital markets, strong relationships within the European life science industry, entrepreneurial flair, and a strong academic background. Most of all, he is committed to enhancing the corporate and shareholder value of innovative life science companies.”